New and emerging treatment approaches to lupus
Open Access
- 1 September 2010
- journal article
- review article
- Published by Taylor & Francis in Biologics: Targets and Therapy
- Vol. 4, 263-271
- https://doi.org/10.2147/BTT.S7581
Abstract
Abstract: The main goal in systemic lupus erythematosus (SLE) is to achieve remission, as this has a major impact on patient and renal survival. Furthermore, early treatment success has been shown to improve long-term prognosis. Treatment in severe SLE, especially in lupus nephritis, has traditionally been a standardized schematic therapy with cyclophosphamide and prednisolone followed by azathioprine. However, animal and human studies have increased our pathogenetic knowledge of this autoimmune disease with emerging new treatment targets. New and future therapeutic approaches are focused on B-cell depletion, T-cell downregulation and co-stimulatory blockade, cytokine inhibition, or the modulation of complement. Many different biological agents have been used in recent and ongoing studies, but up to now breakthroughs emerging from randomized Phase III trials have been rare. However, the future remains exciting with progress towards safe treatments with which to control the disease in the long run.Keywords
This publication has 50 references indexed in Scilit:
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation studyArthritis & Rheumatism, 2010
- Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics RegisterRheumatology, 2010
- Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): Immunomodulation of gene expressionJournal of Autoimmunity, 2009
- Etanercept-associated SLE with lupus nephritisLupus, 2009
- Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and HumansThe International Journal of Cell Cloning, 2009
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412New England Journal of Medicine, 2006
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupusProceedings of the National Academy of Sciences, 2003
- Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosusArthritis & Rheumatism, 2000
- Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule?Immunopharmacology, 1995